- Home
- SVRA vs MREO Comparison
SVRA vs MREO Comparison
Compare SVRA & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRA
- MREO
- Stock Information
- Founded
- SVRA 2007
- MREO 2015
- Country
- SVRA United States
- MREO United Kingdom
- Employees
- SVRA N/A
- MREO 36
- Industry
- SVRA Biotechnology: Pharmaceutical Preparations
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- SVRA Health Care
- MREO Health Care
- Exchange
- SVRA Nasdaq
- MREO Nasdaq
- Market Cap
- SVRA 527.2M
- MREO 281.6M
- IPO Year
- SVRA N/A
- MREO N/A
- Fundamental
- Price
- SVRA $3.72
- MREO $1.77
- Analyst Decision
- SVRA Buy
- MREO Strong Buy
- Analyst Count
- SVRA 7
- MREO 5
- Target Price
- SVRA $6.00
- MREO $7.40
- AVG Volume (30 Days)
- SVRA 1.8M
- MREO 1.2M
- Earning Date
- SVRA 08-13-2025
- MREO 08-12-2025
- Dividend Yield
- SVRA N/A
- MREO N/A
- EPS Growth
- SVRA N/A
- MREO N/A
- EPS
- SVRA N/A
- MREO N/A
- Revenue
- SVRA N/A
- MREO $500,000.00
- Revenue This Year
- SVRA N/A
- MREO N/A
- Revenue Next Year
- SVRA N/A
- MREO $55.50
- P/E Ratio
- SVRA N/A
- MREO N/A
- Revenue Growth
- SVRA N/A
- MREO N/A
- 52 Week Low
- SVRA $1.89
- MREO $1.47
- 52 Week High
- SVRA $4.70
- MREO $4.72
- Technical
- Relative Strength Index (RSI)
- SVRA 82.61
- MREO 51.08
- Support Level
- SVRA $3.19
- MREO $1.68
- Resistance Level
- SVRA $3.28
- MREO $1.83
- Average True Range (ATR)
- SVRA 0.17
- MREO 0.08
- MACD
- SVRA 0.04
- MREO 0.03
- Stochastic Oscillator
- SVRA 88.36
- MREO 73.91
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).